Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by Adagio Therapeutics, Inc. on November 15, 2021, under Item 2.02 to announce a corporate update and financial results for the quarter ended September 30, 2021. The provided filing text does not include the contents of Exhibit 99.1, which contains the referenced press release.
The request identifies Invivyd, Inc.; however, the filing itself identifies the registrant as Adagio Therapeutics, Inc., ticker ADGI.
Financial Metrics
- Revenue, net loss or profit, cash flow, operating expenses, margins, debt, cash, and liquidity figures are not provided in the supplied filing text.
- The filing states that quarterly financial results were announced in the attached press release, but the press release text is not included.
Material Changes Versus Prior Comparable Period
The filing text does not provide clear comparative financial data or quantify changes from the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- The filing states that the company provided a corporate update, but it does not describe management’s guidance, outlook, risks, contingencies, or unusual items.
- The information was furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
- Adagio Therapeutics identified itself as an emerging growth company.
Investor Verification Items
- Verify that the filing relates to Adagio Therapeutics, Inc., not Invivyd, Inc.
- Obtain and review Exhibit 99.1 for the actual quarterly financial results and corporate update.
- Verify cash, liquidity, operating expenses, net loss, cash runway, and any financing or debt information.
- Review management’s stated development priorities, guidance, and risk disclosures.